Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/4705
Title: Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis
Authors: Yaren, Arzu
Oztop, I.
Kargi, A.
Ulukus, C.
Onen, A.
Sanli, A.
Binicier, O.
Keywords: Bax
bcl-2
c-kit
NSCLC
Prognosis
cisplatin
gemcitabine
protein Bax
protein bcl 2
stem cell factor
tyrosine kinase receptor
adult
advanced cancer
age distribution
apoptosis
article
cancer size
cancer staging
cancer survival
cigarette smoking
clinical feature
controlled study
correlation analysis
female
gene expression
histopathology
human
human tissue
large cell carcinoma
lung adenocarcinoma
lung non small cell cancer
lymph node metastasis
major clinical study
male
priority journal
prognosis
squamous cell carcinoma
survival rate
survival time
treatment response
Publisher: Blackwell Publishing Ltd
Abstract: In non-small-cell lung cancer (NSCLC), stage of the disease is still the most important prognostic factor. Other than stage, many biological markers and many other prognostic factors are studied to define their effects on prognosis of lung cancer. In this study, we aimed to evaluate the expressions of Bax and bcl-2 genes which are important in apoptosis and c-kit, which is a tyrosine kinase transmembrane receptor, as well as searched their response to treatment modalities and effects on survival. Sixty-nine NSCLC cases' pathological samples were stained with specific Bax, bcl-2 and c-kit dyes by immunohistochemical (IHC) methods. IHC evaluation was done by the semichantitative method according to the distribution and intensity of the staining. Twelve of 69 cases (17.4%) were stage I, 28 (40.5%) were stage II, 17 were (24.6%) stage IIIA, nine cases were (13.1%) stage IIIB and three cases (4.4%) were stage IV patients. Their histological subtypes were as follows: of 69 cases, 36 (52.2%) were squamous cell carcinoma, 28 (40.6%) were adenocarcinoma, five (7.2%) were adenosquamous cell carcinoma (two patients) and large-cell carcinoma (three patients). The positive immunostaining rates for Bax and bcl-2 in whole group, squamous cell carcinoma and adenocarcinoma groups were 40.6%/36.2%, 55.6/69.4% and 25.0/0.0%, respectively. The positive immune staining rates for c-kit in whole group, squamous cell carcinoma and adenocarcinoma groups were 7.2, 5.6 and 7.1%, respectively. We didn't find any correlation with Bax, bcl-2 and c-kit expressions and clinicopathological parameters such as age, tumour size, lymph node involvement, smoking, stage of the disease, response to radiotherapy and chemotherapy. Results are interpreted according to survival; bax and bcl-2 expressions were not so effective both in whole group and histologically subgrouped patients. C-kit expression was also found not related with survival in whole group whereas found as a bad prognostic factor in patients with squamous cell carcinoma. These findings could indicate that the expression of apoptotic pathway markers and c-kit may have a role in the prognosis of early stage NSCLC, especially with squamous cell carcinoma subtype. © Blackwell Publishing Ltd, 2006.
URI: https://hdl.handle.net/11499/4705
https://doi.org/10.1111/j.1368-5031.2006.00742.x
ISSN: 1368-5031
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

32
checked on Jun 29, 2024

WEB OF SCIENCETM
Citations

26
checked on Jul 10, 2024

Page view(s)

46
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.